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several neurocognitive abilities and to evaluate the safety of this supplementation.
Methods: To	 address	 those	 issues,	 neurocognitive	 performances	were	 explored	by	











this probiotic supplementation appear to have an improvement in some neurocogni-
tive	 functions;	moreover,	 this	 approach	 is	 safe	and	did	not	modify	 significantly	 the	
levels	of	miRNA	in	CSF.	Further	studies	are	needed	to	better	understand	the	contribu-
tion	of	the	probiotics	in	modulating	gut–brain-	axis	in	HIV	patients.
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1  | INTRODUCTION
Probiotic supplementation has become a common practice to control 









ence of a viral infection and associated immunosuppression could be 
a	risk	for	sepsis	and	abscesses	(Haghighat	&	Crum-	Cianflone,	2015).
Few studies have been published on the role of a probiotic sup-
plementation	 on	 SIV+	 monkeys	 and	 on	 HIV+	 humans,	 with	 prom-
ising results regarding the immune reconstitution of the gut barrier 




the effects of a probiotic supplementation on brain function and be-
havior	of	HIV+	subjects.	The	gut	microbiota	 is	 involved	 in	 the	regu-
lation	 of	 cognition,	mood,	 anxiety	 and	 pain	 as	 previously	 shown	by	
studies	performed	in	germ-	free	animal	models	or	in	animals	exposed	
to pathogenic bacterial infections treated by antibiotic drugs or pro-
biotic	 supplementations	 (Cryan	&	Dinan,	 2012).	The	 gut	microbiota	
can	impact	mood	and	cognitive	functions	(Desbonnet,	Garrett,	Clarke,	
Bienenstock,	&	Dinan,	2008;	Desbonnet	et	al.,	2010)	in	different	ways,	
i.e.,	 by	 producing	 neuroactive	 substances	 or	 releasing	 bacterial	 by-	
products and metabolites.





otic	 (Vivomixx®	Visbiome®) supplementation on neuropsychological 
tests	exploring	several	neurocognitive	abilities	and	(2)	to	evaluate	the	
safety of this supplementation.
The primary endpoint aimed at evaluating the effect of this specific 




bal	 fluency	 (Frontal	Assessment	Battery,	 FAB;	Test	 of	Phonological/
Semantic	Verbal	Fluency,	PVF/SVF),	working	memory’s	number	stor-
age	capacity	and	short-	term	memory	(Back	and	Forward	Digit-	Verbal	
Span),	visuospatial	 short-	term	working	memory	 (Corsi	 block-	tapping	
test,	 CBTT),	 visual	 attention	 and	 task	 switching	 (Trail	 making	 test,	
TMT),	and	frontal	functions	(Time	and	weight	estimation	test,	STEP).
To	evaluate	the	safety	of	the	product	at	the	neurological	 level,	a	
lumbar puncture before and after the probiotic supplementation was 
performed. Due to the invasive procedure of the lumbar puncture and 
associated	 risks,	 a	 control	 group	 was	 excluded.	 CSF	 miRNA-	29a-	c	
levels	were	 evaluated.	miRNAs	 are	 short	 single-	stranded	noncoding	




2  | MATERIALS AND METHODS
2.1 | Study design, recruitment, and study eligibility 
criteria
This	is	a	longitudinal,	nonrandomized	designed,	single-	arm,	pilot	study	




ies/ml,	 and	 CD4	 counts	 >400	cells/mm3.	 Exclusion	 criteria	 were:	 











ing	 and	 lumbar	 puncture	 before	 (T0)	 and	 after	 (T6)	 probiotic	 sup-
plementation	of	cART,	 in	 this	way,	each	patient	was	 the	control	of	
oneself.	(Figure	1).	Because	lumbar	puncture	is	considered	a	proce-
dure with several risks and in literature there is no reported study 
where	 lumbar	 puncture	 was	 performed	 in	 the	 control	 arm,	 our	
Institution considered it unethical to have a control group undergo-





paracasei	DSM	24733,	Lactobacillus delbrueckii subsp. bulgaricus	DSM	
24734,	Lactobacillus acidophilus	DSM	24735,	Bifidobacterium longum 
DSM	24736,	 and	Bifidobacterium infantis	 DSM	 24737)	 produced	 at	
K E Y W O R D S
HIV,	miRNA,	miRNA-29,	neuropsychological	performance,	probiotics
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Danisco	 Dupont,	WI,	 USA	 and	 currently	 sold	 in	 Europe	 under	 the	
brand	Vivomixx®	and	in	the	USA	as	Visbiome®.
2.2 | Ethics statement
The researchers declare compliance with ethical practices upon sub-
mission of a manuscript and that clinical investigations were con-
ducted	 according	 to	 the	 principles	 expressed	 in	 the	Declaration	 of	
Helsinki.	The	study	was	approved	after	amendment	(no	control	group	
and lumbar puncture to the untreated subjects) by the institutional 
review	board	(Department	of	Public	Health	and	Infectious	Diseases,	
“Sapienza”	University	of	Rome	and	the	Ethics	Committee	of	Umberto	
I	 General	Hospital,	 Rome)	 on	 16th	 January	 2014.	 All	 study	 partici-
pants gave written informed consent. The authors declare that the 
Department of Public Health and Infectious Disease where patients 
were recruited is fully equipped for the planned interventions. The 












of	 tests	 to	 explore	 the	main	 cognitive	domains	 (memory,	 attention,	
executive	function,	and	language)	(Belleville,	Rouleau,	&	Caza,	1998;	















same	 time,	 to	 assess	 psychological	 manifestations	 (alexithymia,	 de-
pression,	state	and	trait	anxiety),	all	patients	were	evaluated	through	
a	 set	 of	 questionnaires:	 Toronto	Alexithymia	 Scale-	20	 (Bressi	 et	al.,	






tion levels as required to the normative standards based on the rela-
tive	Italian	validation	manuals	(Barletta-	Rodolfi,	Gasparini,	&	Ghidoni,	
2011).	All	the	tests	with	the	relative	validation	chosen	for	our	battery,	
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2008).	The	tests	used	are	standard	normalized	tests	for	which	normal	
subject performances are known.
2.5 | TaqMan- based real- time RT- PCR technique 
for microRNAs
MicroRNAs	were	quantified	by	real-	time	RT-	PCR	Taqman	assays	(hsa-	




using	 a	 TaqMan	MicroRNA	Reverse	 Transcription	Kit,	 according	 to	
the	 manufacturer’s	 protocols	 (Applied	 Biosystems).	 Real-	time	 PCR	
was carried out in a final volume of 20 μl	using	a	LightCycler480	in-





















Differences were considered statistically significant when p	<	.05.
3  | RESULTS
3.1 | Demographic and clinical characteristics of 
HIV- 1- positive patients
All	 subjects	 enrolled	 were	 HIV-	1-	infected	 Caucasian	 men	 with	 a	













3.2 | Neuropsychological performance after 
probiotic supplementation
A	battery	 of	 neuropsychological	 tests	was	 administered	 to	 all	HIV-	1-	
positive	patients	before	(T0)	and	after	6	months	of	probiotic	supplemen-
tation	(T6).	The	tests	were	readministered	after	6	months	and	a	parallel	
form	was	used	 for	RAVLT	 (immediate	 and	delayed	 recall)	 the	parallel	
form,	according	to	the	Italian	validation.	 (Barletta-	Rodolfi	et	al.,	2011).	
None of the patients studied had received prior neurocognitive tests.
The results of neuropsychological tests are showed in Table 1. In 
particular,	we	observed	 a	 significant	 difference	between	T0	 and	T6	
for	immediate	and	delayed	recall	of	RAVLT	(immediate:	p = .0273; de-
layed: p	=	.0299),	immediate	and	delayed	recall	of	ROCF	(immediate:	
p	=	.0058;	delayed:	p	=	.0019).
Also,	PVF	(p	=	.0137),	STEP	(time:	p = .0246; weight: p	=	.022),	Tas-	
20	 (p	=	.0421),	 STAY	Y-	2	 (p	=	.0225),	 and	CBTT-	Forward	 (p = .0322) 
test	scores	increased	significantly	in	HIV-	1-	positive	patients	who	took	
probiotics twice a day for 6 months.
By	contrast,	 no	 significant	differences	were	observed	 for	 the	other	
neuropsychological	test	scores	examined	before	and	after	probiotic	intake.
3.3 | Expression of microRNA- 29a- c
The	 analysis	 of	 miRNA-	29a-	c	 levels	 in	 CSF	 collected	 from	 HIV-	1-	
infected	patients	before	(T0)	and	after	6	months	of	daily	 (T6)	probi-
otic supplementation showed a high degree of individual variability in 
miRNA-	29	levels	[coefficient	of	variation	(%):	T0	(miRNA-	29a:	91.30;	
miRNA-	29b:	135.858;	miRNA-	29c:	119.93);	T6	(miRNA-	29a:	118.54;	
miRNA-	29b:	 156.46;	 miRNA-	29c:	 160.32)].	 After	 probiotic	 supple-
mentation,	miRNA-	29a-	c	levels	and	the	pattern	of	miRNA-	29	expres-
sion remained unchanged.
3.4 | Bacterial DNA isolation from fecal samples
We found that fecal Bifidobacteria spp. increased significantly in all 
patients	compared	to	their	basal	level,	after	2	months	of	supplementa-
tion	(p	<	.05)	and	remained	stable	through	the	study	(data	not	shown)	
and this was considered as a proof of compliance to the treatment.
3.5 | Safety of probiotic supplementation
All	patients	received	a	high-	concentration	lyophilized	multistrain	pro-
biotic	powder	supplement	twice	a	day	for	6	months	(1.8	×	109). This 
dosage was well- tolerated throughout the course of the study and 
side effects were not reported.
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4  | DISCUSSION
Neurocognitive disorder affects more than 50% of antiretroviral- 
treated	HIV	 subjects	 (Heaton	 et	al.,	 2010).	 An	 improvement,	 but	
not	 complete	 recovery,	 of	 neurocognitive	 impairment	 has	 been	
reported	in	the	literature,	but	only	after	the	cART	was	intensified	
which often is not a feasible avenue due to the untoward effects 
and	chronic	nature	of	the	disease	(Stilling,	Dinan,	&	Cryan,	2014).	
We	hypothesized	 that	a	new	and	safe	approach	 for	 the	 improve-
ment of the neuropsychological performance of these subjects 
could	be	 the	 administration	of	 probiotics.	 In	 the	 last	 years,	 there	
has	been	an	 increase	 in	experimental	 research,	 conducted	mainly	
on	 animals,	 aimed	 to	 explore	 the	 contribution	 of	 the	 microbiota	
in	 modulating	 gut–brain-	axis	 (GBA).	 The	 discovery	 that	 differen-
tial microbial composition is associated with alterations in behav-
ior and cognition has significantly contributed to establish the 




Recent	 studies	 exploring	 the	 effects	 of	 different	 gut	microbiota	
composition on impairment of cognition and behavior have shown 
that	alterations	of	microbioma	composition	are	connected	to	stress,	
modification	of	mood	and	behavior,	worsening	of	cognition	and	that	
probiotics	 can	 play	 a	 protective	 role	 (Carabotti,	 Scirocco,	Maselli,	 &	
Severi,	 2015;	 Jiang	 et	al.,	 2015;	 Steenbergen,	 Sellaro,	 van	 Hemert,	
Bosch,	&	Colzato,	2015).
Since	no	data	were	available,	our	primary	study	end	point	was	to	
verify the safety of a high- concentration multistrain probiotic supple-
mentation at the neurological level. Each patient underwent a lumbar 
puncture before and after probiotic supplementation to verify any 
changes	in	CSF.
All	 HIV-	1-	positive	 patients	 received	 a	 high-	concentration	 lyo-
philized	 multistrain	 probiotic	 powder	 supplement	 twice	 a	 day	 for	
6	months	 (1.8	×	10^9).	 This	 dosage	 was	 well-	tolerated	 throughout	
the course of the study and the potential side effects which had 
been previously reported for other and different formulations were 
not	reported	here	(Anukam,	Osazuwa,	Osadolor,	Bruce,	&	Reid,	2008;	
Haghighat	 &	 Crum-	Cianflone,	 2015;	 Hummelen	 et	al.,	 2011).	 We	
found that fecal Bifidobacteria spp increased in all patients compared 
TABLE  1 Results of neuropsychological test administered before and after 6 months of probiotic supplementation
T0 – median (interquartile range) T6 – median (interquartile range) p value
















FAB	(Frontal	Assessment	Battery) 14.85	(13.60–15.80) 15.45	(14.21–17.50) .1780
PVF	(Phonological	Verbal	Fluency) 28.50	(22.82–37.88) 43.95	(42.25–44.75) .0137
SVF	(Semantic	Verbal	Fluency) 47.00	(32.75–54.75) 48.50	(45.50–49.00) .3580
TMTA	(Trail	Making	Test	A) 50.00	(44.25–55.00) 46.00	(40.50–54.00) .1395
TMTB	(Trail	Making	Test	B) 117.50	(99.50–122.80) 125.00	(98.50–138.50) .9527
Verbal	Span-	Digit	Forward 4.50	(3.50–5.37) 5.00	(5.00–5.81) .0940
Verbal	Span-	Digit	Back 4.50	(4.00–5.00) 5.00	(4.25–5.00) .5716
Tas-	20	(Toronto	Alexithymia	Scale-	20) 40.00	(35.00–41.00) 50.00	(41.00–54.00) .0421
BDI-	II	(Beck	Depression	Scale	II)
STAY	Y-	1	(State-	Trait	Anxiety	Inventory) 47.00	(45.00–50.00) 55.00	(50.00–70.00) .0751
STAY	Y-	2	(State-	Trait	Anxiety	Inventory) 60.00	(40.00–65.00) 85.00	(65.00–90.00) .0225
AAT	(Aachen	Aphasia	Test) 9.00	(9.00–9.00) 9.00	(9.00–9.00) 1.0000
CBTT-	Forward	(Corsi	block-	tapping	task) 4.37	(4.00–5.00) 5.25	(5.05–5.44) .0322
CBTT-	Backward	(Corsi	block-	tapping	task) 4.00	(3.00–4.00) 4.00	(4.00–4.75) .1198
STEP	Time	(Time	and	Weight	Estimation	test) 16.50	(13.25–22.25) 23.00	(21.25–23.00) .0246
STEP	Weight	(Time	and	Weight	Estimation	test) 19.00	(15.00–19.75) 21.00	(21.00–23.00) .0220
STEP	Total	(Time	and	Weight	Estimation	test) 36.50	(29.75–44.25) 44.50	(43.00–45.00) .0827
Significantly	different	values	are	highlighted	in	bold.
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to	their	basal	level,	at	2	months	of	supplementation	and	remained	sta-







Moreover,	 our	 patients	 presented	 a	 relevant	 improvement	 of	









it has been highlighted that a crucial role in the bidirectional commu-
nication	of	 the	gut–brain-	axis,	 is	covered	by	the	hypothalamic–pitu-
itary	adrenal	(HPA)	axis.	As	well	known,	the	HPA	axis	is	considered	the	





tation seems to be a safe dietary approach to improve neurocognitive 
performance	 in	 HIV-	1-	positive	 patients,	 in	 particular	memory	 func-
tions. The same multistrain high- concentration probiotic has been 
shown	to	increase	the	brain-	derived	neurotrophic	factor	(BDNF)	ex-











the	 level	of	alexithymia	and	on	 the	STAY-	Y2	 test,	 that	on	 the	other	
hand,	 in	used	to	measure	the	 level	of	the	anxiety	of	the	patients.	 In	
our	opinion,	based	on	clinical	observation	and	clinical	interviews,	the	
increase of these variables could be due to an increased awareness 
of	the	underlying	disease,	also	reported	by	the	patients	 themselves,	
leading	also	to	the	improvement	of	cognitive	functions.	However,	this	
hypothesis needs further observations.
On	the	basis	of	our	results,	HIV-	positive	patients	treated	with	pro-
biotic supplementation improved their performance significantly in 
some	neurocognitive	domains	 (short	 and	 long	memory	and	abstract	
reasoning),	 while	 their	 abilities	 did	 not	 vary	 in	 the	 other	 domains	
explored.	 At	 this	 moment,	 the	 origin	 of	 this	 clinical	 observation	 is	
unknown.	As	previous	reported,	possible	reason	might	be	due	to	the	
fact that hippocampal regions are involved only in certain aspects of 
neurocognitive	 processes,	 but	 further	 studies	 are	 needed	 to	 under-
stand	this	topic.	Moreover,	we	cannot	rule	out	that	the	power	of	sta-
tistical	 analysis	 has	 been	 reduced	 by	 the	 sample	 size	 of	 the	 cohort	
studied.
This	 study	suffers	 for	 the	 small	 sample	 size	and	 the	 related	sta-
tistical concerns and lacks proper control for multiple correlations. 
However,	the	small	sample	size	 is	 justified	by	the	need	to	verify	the	
safety of this high- concentration multistrain probiotic supplemen-
tation.	 Usually,	 few	 thousand	 million	 probiotic	 bacteria	 have	 been	
administered	 to	AIDS	patients	 and	a	prudent	 approach	 (pilot	 study)	
consequently	was	mandatory.	It	is	evident	that	a	small	sample	size	lim-
its	the	capability	to	analyze	properly	the	results	from	a	statistical	point	
of	view.	However,	 in	 the	 field	of	HIV	many	studies	have	been	pub-
lished even when the number of patients was limited and no control 
group was enrolled as their observations and results prompted larger 
confirmatory	trials.	Moreover,	another	limitation	of	our	study	was	the	
absence	of	a	control	group.	The	reasons	that	explain	the	absence	of	
a control group are essentially related to restrictions indicated by the 
ethics	committee,	namely:	(1)	lumbar	puncture	presents	several	risks	
(i.e.,	seeding	of	infection	to	the	CSF;	epidermoid	tumor	implantation;	
uncal or transtentorial herniation and neurological deterioration; spi-
nal	 hematoma),	 for	 these	 reasons,	 performing	 this	 procedure	 on	 a	
control group of healthy subjects was not considered acceptable by 
the	ethics	committee;	 (2)	 in	addition,	 the	use	of	placebo	 in	HIV	pa-
tients	under	heavy	cART	medication	is	discouraged;,	and	(3)	 last	but	
not	least,	since	the	product	we	administered	is	a	probiotic,	the	placebo	
group should have been on a dietary restriction for all the fermented 
foods	containing	bacterial	species	 (yogurt,	kefir,	sour	cream,	cheese,	
crème	 fraiche,	 salami,	vinegar,	 fish	 sauce,	 etc.).	Unnecessary	dietary	
restrictions	to	HIV-	positive	subjects	are	not	considered	ethically	ac-
ceptable by our Institution.
Furthermore,	although	our	data	suggest	the	improvement	of	some	
cognitive	domains,	we	cannot	 totally	 exclude	 the	possible	 influence	









otic formulation twice a day for 6 months had significantly improved 
some	 neurological	 cognitive	 functions	 (short	 and	 long	memory	 and	
abstract	 reasoning),	 thus	 supporting	 the	 concept	 that	modifications	
of	the	gut	flora	can	provide	specific	neurological	benefits	in	HIV-	1	pa-
tients in the absence of significant side effects.
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